clinical medical

Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study

Share

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has reported full 2-year clinical results from its ARTISAN-SNM pivotal study.  Read more.

Source: Business Wire, September 10, 2020

Posted in News and tagged , , , , .